Oneness Biotech Co Ltd

LEO Pharma A/S has hit the mark a second time in a clinical trial program meant to expand its competitive positioning in dermatology with the news that a second Phase III study of its topical JAK inh

LEO Pharma A/S 's celebrations at getting the European Medicines Agency's backing for tralokinumab last week have ground to an abrupt halt after regulators in the US rejected the Danish group's biolog

Dermatology specialist LEO Pharma A& is preparing to launch the interleukin-13 inhibitor tralokinumab for atopic dermatitis in the US in 2021, where it will compete against a well-entrenched rival,

Exerting maximum influence on stakeholders, helping companies navigate regulatory complexity and promoting industry best practice are three big jobs that the UK consumer healthcare industry associatio